Overview
-
-
-
- Ask Iris
- Portfolio
- Alerts
- Discovery
- Pricing
- Toolkit
Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
₹663.12
▲ 0.44
(0.07%)
11 Nov 2026
| Instrument Name | Watchlist | Investment Date | % Holding | No of Units | Value (₹ Cr) | Asset Type | Industry Name |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical ... | 31 Oct 2026 | 11.55% | 59,06,349 | ₹1,049.97 Cr | Equity | Pharmaceuticals | |
 Divis Laboratories Ltd | 31 Oct 2026 | 6.73% | 6,25,754 | ₹611.99 Cr | Equity | Pharmaceuticals | |
 Cipla Ltd | 31 Oct 2026 | 6.21% | 40,95,054 | ₹564.67 Cr | Equity | Pharmaceuticals | |
 Lupin Ltd | 31 Oct 2026 | 6.16% | 27,83,991 | ₹559.86 Cr | Equity | Pharmaceuticals | |
| Dr Reddys Laborator... | 31 Oct 2026 | 6.13% | 41,18,506 | ₹556.82 Cr | Equity | Pharmaceuticals | |
 Apollo Hospitals En... | 31 Oct 2026 | 5.10% | 5,48,795 | ₹463.62 Cr | Equity | Healthcare | |
 Mankind Pharma Ltd | 31 Oct 2026 | 4.40% | 16,03,562 | ₹399.74 Cr | Equity | Pharmaceuticals | |
| Sai Life Sciences Ltd | 31 Oct 2026 | 4.04% | 23,55,745 | ₹366.91 Cr | Equity | Pharmaceuticals | |
| Ajanta Pharma Ltd | 31 Oct 2026 | 3.53% | 9,13,918 | ₹320.68 Cr | Equity | Pharmaceuticals | |
| Max Healthcare Inst... | 31 Oct 2026 | 3.31% | 34,98,082 | ₹300.84 Cr | Equity | Healthcare |
Funds in the same category by AUM
You can invest in Nippon India Pharma Fund - Direct (G) through a lump sum investment or a monthly SIP. The minimum lump sum investment is ₹5,000 and the minimum SIP amount is ₹100.
The latest NAV of Nippon India Pharma Fund - Direct (G) is ₹663.12.
Nippon India Pharma Fund - Direct (G) manages assets worth ₹9,087.25 Cr.
The expense ratio of Nippon India Pharma Fund - Direct (G) is 0.99%.
The exit load applicable on Nippon India Pharma Fund - Direct (G) is 1% if redeemed or switched out on or before completion of 1 Months from the date of allotment of units. Nil if redeemed or switched out after the completion of 1 Months from the date of allotment of units..
As per the riskometer, Nippon India Pharma Fund - Direct (G) carries Very High risk.
Nippon India Pharma Fund - Direct (G) is managed by Nippon India Mutual Fund.
Nippon India Pharma Fund - Direct (G) belongs to the Sectoral Fund category.
Nippon India Pharma Fund - Direct (G) is benchmarked against the BSE Healthcare TRI.
Nippon India Pharma Fund - Direct (G) has no lock-in period, so units can be redeemed at any time subject to the applicable exit load.
Nippon India Pharma Fund - Direct (G) was launched on 02 Jan 2013.
After the initial investment, you can invest in Nippon India Pharma Fund - Direct (G) in further multiples of ₹1,000.
The primary investment objective of the Scheme is to generate consistent returns by investing in equity / equity related or fixed income securities of Pharma and other associated companies
The primary investment objective of the Scheme is to generate consistent returns by investing in equity / equity related or fixed income securities of Pharma and other associated companies
02 Jan 2013
₹9,087.25 Cr
₹663.12
₹100
₹5,000
Very High
0.99%
12.37
0.65
0.84
4.29
0.59
0.04
0.15
| Company | Watchlist | Sector | Activity | Investment Date | % Holding | Market Value | Shares | Asset Type | Rating |
|---|---|---|---|---|---|---|---|---|---|
 Natco Pharma Ltd | Pharmaceuticals -... | Bought | 31 Oct 2026 | 0.90% | ₹81.37 Cr | 10,40,000 | Equity | EQUITY | |
| Molbio Diagnostics Ltd | Medical Equipment | Bought | 31 Aug 2026 | 0.44% | ₹41.31 Cr | 3,80,293 | Equity | EQUITY |
This fund has Very High risk.
Returns over a year are annualised (per year, compounded).
Calendar year return from the first period shown through each year.
Funds in the same category by AUM
| Fund | Watchlist | AMC | NAV | Fund Size | Expense Ratio | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|
 ICICI Pru Technology Fund... | ICICI Prudential Mutual Fund | ₹209.48 | ₹13,154.25 Cr | 1.21% | -4.57% | 8.38% | 3.53% | |
 HDFC Defence Fund - Direc... | HDFC Mutual Fund | ₹30.34 | ₹11,130.70 Cr | 0.90% | 21.17% | 34.08% | — | |
| ICICI Pru Banking & Finan... | ICICI Prudential Mutual Fund | ₹155.70 | ₹10,708.73 Cr | 1.25% | -0.36% | 11.83% | 9.47% | |
 SBI Banking & Financial S... | SBI Mutual Fund | ₹51.65 | ₹10,505.22 Cr | 1.18% | 2.28% | 17.67% | 12.41% | |
 Tata Digital India Fund -... | Tata Mutual Fund | ₹49.97 | ₹9,985.39 Cr | 0.67% | -7.12% | 6.70% | 3.34% | |
| Nippon India Pharma Fund ... | Nippon India Mutual Fund | ₹663.12 | ₹9,087.25 Cr | 0.99% | 16.10% | 18.86% | 15.30% |
| Fund | 1Y | 3Y | Expense Ratio | Fund Size | Alpha | Sharpe | Risk | |
|---|---|---|---|---|---|---|---|---|
| Nippon India Pharma Fund - Di... | 16.10% | 18.86% | 0.99% | ₹9,087.25 Cr | 12.37 | 0.84 | Very High | |
| ICICI Pru Healthcare Fund - D... | 12.15% | 22.47% | 1.30% | ₹7,103.54 Cr | 15.70 | 0.98 | Very High | |
 DSP Healthcare Fund - Direct (G) | 19.74% | 21.97% | 0.75% | ₹3,727.17 Cr | 14.89 | 0.99 | Very High | |
 Mirae Asset Healthcare Fund -... | 28.66% | 24.62% | 0.61% | ₹3,562.24 Cr | 17.00 | 1.08 | Very High | |
| Tata India Pharma & Healthcar... | 11.00% | 19.14% | 1.09% | ₹1,499.08 Cr | 13.18 | 0.81 | Very High | |
 UTI-Healthcare Fund - Direct (G) | 22.48% | 24.09% | 1.34% | ₹1,432.88 Cr | 16.63 | 1.05 | Very High | |
 Aditya Birla SL Pharma & Heal... | 21.92% | 21.21% | 1.05% | ₹1,087.96 Cr | 14.60 | 0.96 | Very High |